Vera Therapeutics (VERA) Share-based Compensation (2020 - 2026)

Vera Therapeutics' Share-based Compensation history runs 7 years deep, the most recent figure standing at $13.2 million for Q1 2026.

• Quarterly Share-based Compensation rose 70.56% year-over-year to $13.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $43.4 million (up 77.67% YoY) and the FY2025 annual result came in at $66.0 million, up 33.87% from the prior year.
• Share-based Compensation was $13.2 million for Q1 2026 at Vera Therapeutics, up from $11.0 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $13.2 million in Q1 2026 and bottomed at -$4.1 million in Q4 2022.
• A 5-year average of $5.0 million and a median of $4.1 million in 2024 frame the typical range for Share-based Compensation.
• Peak annual rise in Share-based Compensation reached 311.39% in 2022, while the deepest fall reached 530.25% in 2022.
• Vera Therapeutics' Share-based Compensation stood at -$4.1 million in 2022, then soared by 177.82% to $3.2 million in 2023, then soared by 93.01% to $6.2 million in 2024, then soared by 76.37% to $11.0 million in 2025, then grew by 20.46% to $13.2 million in 2026.
• Business Quant data shows VERA's Share-based Compensation at $13.2 million in Q1 2026, $11.0 million in Q4 2025, and $9.7 million in Q3 2025.